Indaptus Therapeutics, Inc.
INDPDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Q2 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Decoy20 | Phase 2 | Solid Tumor, Adult | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Indaptus Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Indaptus Therapeutics, Inc.'s (INDP) pipeline across Phase 2. Its lead program is Decoy20 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Indaptus Therapeutics, Inc.'s next FDA catalyst?→
Indaptus Therapeutics, Inc.'s (INDP) next tracked catalyst is a Phase 2 expected June 30, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track INDP biotech catalysts?→
Add INDP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Indaptus Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.